Datasheet for ABIN135677

anti-CD9 antibody

1 Image | 1 Publication

Go to Product page

Overview

Quantity:	0.1 mg
Target:	CD9
Reactivity:	Human
Host:	Mouse
Clonality:	Monoclonal
Conjugate:	This CD9 antibody is un-conjugated
Application:	Flow Cytometry (FACS)

Product Details

Immunogen:	Unknown
Clone:	MM2-57
Isotype:	IgG2b
Specificity:	Human/Hamster/Canine/Feline/Monkey/Rabbit/Raccoon CD9, Mr 24 kDa
Characteristics:	Mouse Anti-Human CD9-UNLB
Purification:	Purified

Target Details

Target:	CD9
Alternative Name:	CD9 (CD9 Products)
Background:	CD9 is a 24 kDa member of the transmembrane 4 superfamily (TM4-SF) of cell surface

Target Details

	receptors. It is expressed strongly on platelets, lymphoid progenitor cells, activated lymphocytes and endothelia, and, weakly, on eosinophils, granulocytes, monocytes, and macrophages. CD9 functions as an adhesion molecule where it mediates platelet aggregation and activation.
Pathways:	Response to Water Deprivation, Cell-Cell Junction Organization

Application Details

Application Notes:	• **Applications:** FC - Quality tested , IHC-FS - Reported in literature , ICC - Reported in literature , IP - Reported in literature , WB - Reported in literature • **Working Dilutions:** Flow Cytometry Purified (UNLB) antibody 1 g/106 cells FITC and PE conjugates 10 L/106 cells For flow cytometry, the suggested use of these reagents is in a final volume of 100 L
Comment:	platelet inhibition and aggregation studies
Sample Volume:	1 mL
Restrictions:	For Research Use only

Handling

Concentration:	0.1 mg/mL
Buffer:	0.1 mg of purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. No preservatives or amine-containing buffer salts added
Preservative:	Without preservative
Handling Advice:	Each reagent is stable for the period shown on the bottle label if stored as directed.
Storage:	4 °C
Storage Comment:	Store at 2-8°C

Publications

Product cited in:	Kamisasanuki, Tokushige, Terasaki, Khai, Wang, Sakamoto, Kosai: "Targeting CD9 produces stimulus-independent antiangiogenic effects predominantly in activated endothelial cells during angiogenesis: a novel antiangiogenic therapy." in: **Biochemical and biophysical research communications**, Vol. 413, Issue 1, pp. 128-35, (2011) (PubMed).



Flow Cytometry

Image 1. Human peripheral blood platelets were stained with Mouse Anti-Human CD9-FITC.